-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Stifel Downgrades Fate Therapeutics to Hold, Lowers Price Target to $5.3

Benzinga · 01/06/2023 07:54
Stifel analyst Benjamin Burnett downgrades Fate Therapeutics (NASDAQ:FATE) from Buy to Hold and lowers the price target from $107 to $5.3.